BioAge Labs (BIOA) Treasury Shares (2023 - 2024)

BioAge Labs (BIOA) reported Treasury Shares of $93.1 million for Q2 2024, little changed sequentially from $93.1 million in Q1 2024.

BioAge Labs (BIOA) Treasury Shares (2023 - 2024) Analysis & Trends

BioAge Labs (BIOA) has 2 years of Treasury Shares data on file, last reported at $93.1 million in Q2 2024.

For the quarter ending Q2 2024, Treasury Shares changed N/A year-over-year to $93.1 million; the trailing twelve-month figure through Jun 2024 stood at $93.1 million (changed N/A YoY), and the FY2023 full-year result was $31.5 million, changed N/A from the prior year.
Treasury Shares held at $93.1 million in Q2 2024, from $93.1 million in the prior quarter.
In the past five years, Treasury Shares ranged from a high of $93.1 million in Q1 2024 to a low of $31.5 million in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	62.52 Mn
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	107.00 Mn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	11.29 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	313.27 Mn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	5.44 Bn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	1.01 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	-
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	-
10	BioAge Labs	930.32 Mn	930.32 Mn	-10.37 Mn	-

Download Data